Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee Regarding Lofexidine

March 27, 2018

View as PDF.

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Psychopharmacologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject WorldMeds’s new drug application for lofexidine for the symptomatic treatment of opioid withdrawal because the maximum dose for which approval is being sought is significantly more dangerous but no more effective than lower doses used in the UK.